These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 18474499)

  • 21. Multidrug-experienced HIV-1-infected women demonstrated similar virological and immunological responses to tipranavir/ritonavir compared with men.
    Walmsley SL; Squires K; Weiss L; Easterbrook P; Orani A; Kraft M; Scherer J
    AIDS; 2009 Jan; 23(3):429-31. PubMed ID: 19114862
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Changes in darunavir/r resistance score after previous failure to tipranavir/r in HIV-1-infected multidrug-resistant patients.
    Spagnuolo V; Gianotti N; Seminari E; Galli L; Fusetti G; Salpietro S; Lazzarin A; Castagna A
    J Acquir Immune Defic Syndr; 2009 Feb; 50(2):192-5. PubMed ID: 19131889
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Unexpected drug-drug interaction between tipranavir/ritonavir and enfuvirtide.
    González de Requena D; Calcagno A; Bonora S; Ladetto L; D'Avolio A; Sciandra M; Siccardi M; Bargiacchi O; Sinicco A; Di Perri G
    AIDS; 2006 Oct; 20(15):1977-9. PubMed ID: 16988521
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Switch from enfuvirtide to raltegravir lowers plasma concentrations of darunavir and tipranavir: a pharmacokinetic substudy of the EASIER-ANRS 138 trial.
    Goldwirt L; Braun J; de Castro N; Charreau I; Barrail-Tran A; Delaugerre C; Raffi F; Lascoux-Combe C; Aboulker JP; Taburet AM; Molina JM
    Antimicrob Agents Chemother; 2011 Jul; 55(7):3613-5. PubMed ID: 21576452
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Provider prescribing of 4 antiretroviral agents after implementation of drug use guidelines in the Department of Veterans Affairs.
    Belperio PS; Mole LX; Boothroyd DB; Backus LI
    J Manag Care Pharm; 2009 May; 15(4):323-34. PubMed ID: 19422272
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [New therapeutic options in protracted HIV-infected patients with virological failure].
    Moreno Cuerda VJ; Rubio García R; Morales Conejo M
    Med Clin (Barc); 2008 Jan; 130(2):66-70. PubMed ID: 18221677
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An update and review of antiretroviral therapy.
    Piacenti FJ
    Pharmacotherapy; 2006 Aug; 26(8):1111-33. PubMed ID: 16863488
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anti-HIV agents. Tipranavir in treatment-experienced PHAs.
    TreatmentUpdate; 2005; 17(1):4-5. PubMed ID: 17225315
    [No Abstract]   [Full Text] [Related]  

  • 29. Hepatic safety of tipranavir plus ritonavir (TPV/r)-based antiretroviral combinations: effect of hepatitis virus co-infection and pre-existing fibrosis.
    Macías J; Orihuela F; Rivero A; Viciana P; Márquez M; Portilla J; Ríos MJ; Muñoz L; Pasquau J; Castaño MA; Abdel-Kader L; Pineda JA;
    J Antimicrob Chemother; 2009 Jan; 63(1):178-83. PubMed ID: 18952618
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tipranavir: new drug. HIV protease inhibitor. A last resort.
    Prescrire Int; 2006 Dec; 15(86):217-9. PubMed ID: 17167925
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of darunavir/ritonavir plus etravirine dual regimen in antiretroviral therapy-experienced patients: a multicenter clinical experience.
    Gazzola L; Cicconi P; Ripamonti D; Di Filippo E; Gustinetti G; Di Biagio A; Marchetti G; Bini T; d'Arminio Monforte A
    HIV Clin Trials; 2014; 15(4):140-50. PubMed ID: 25143023
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Resilience to resistance of HIV-1 protease inhibitors: profile of darunavir.
    Lefebvre E; Schiffer CA
    AIDS Rev; 2008; 10(3):131-42. PubMed ID: 18820715
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Porphyria cutanea tarda in an HIV-1-infected patient after the initiation of tipranavir/ritonavir: case report.
    Celesia BM; Onorante A; Nunnari G; Mughini MT; Mavilla S; Massimino SD; Russo R
    AIDS; 2007 Jul; 21(11):1495-6. PubMed ID: 17589203
    [No Abstract]   [Full Text] [Related]  

  • 34. Tipranavir.
    Gallant J
    Drugs; 2003; 63(15):1619-20. PubMed ID: 12887269
    [No Abstract]   [Full Text] [Related]  

  • 35. Darunavir: after multiple antiretroviral treatment failure: another option.
    Prescrire Int; 2008 Jun; 17(95):109. PubMed ID: 18629967
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evidence for different susceptibility to tipranavir and darunavir in patients infected with distinct HIV-1 subtypes.
    Poveda E; de Mendoza C; Parkin N; Choe S; García-Gasco P; Corral A; Soriano V
    AIDS; 2008 Mar; 22(5):611-6. PubMed ID: 18317002
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Tipranavir (used with ritonavir)].
    Taéron C
    Rev Infirm; 2006 Jan; (117):39-40. PubMed ID: 16502825
    [No Abstract]   [Full Text] [Related]  

  • 38. Treatment simplification to once daily darunavir/ritonavir guided by the darunavir inhibitory quotient in heavily pretreated HIV-infected patients.
    Moltó J; Valle M; Santos JR; Mothe B; Miranda C; Cedeño S; Negredo E; Yritia M; Videla S; Barbanoj MJ; Clotet B
    Antivir Ther; 2010; 15(2):219-25. PubMed ID: 20386077
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tipranavir: a protease inhibitor for HIV salvage therapy.
    Dong BJ; Cocohoba JM
    Ann Pharmacother; 2006; 40(7-8):1311-21. PubMed ID: 16788094
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Switching to darunavir/ritonavir 800/100 mg once-daily containing regimen maintains virological control in fully suppressed pre-treated patients infected with HIV-1.
    Ghosn J; Slama L; Chermak A; Houssaini A; Lambert-Niclot S; Schneider L; Fourn E; Duvivier C; Simon A; Courbon E; Murphy R; Flandre P; Peytavin G; Katlama C;
    J Med Virol; 2013 Jan; 85(1):8-15. PubMed ID: 23024008
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.